Logo image of SNSE

SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SNSE - US81728A2078 - Common Stock

10.44 USD
-1.17 (-10.08%)
Last: 1/16/2026, 8:00:02 PM
Fundamental Rating

2

Overall SNSE gets a fundamental rating of 2 out of 10. We evaluated SNSE against 529 industry peers in the Biotechnology industry. While SNSE has a great health rating, there are worries on its profitability. SNSE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SNSE had negative earnings in the past year.
  • In the past year SNSE has reported a negative cash flow from operations.
  • SNSE had negative earnings in each of the past 5 years.
  • SNSE had a negative operating cash flow in each of the past 5 years.
SNSE Yearly Net Income VS EBIT VS OCF VS FCFSNSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -87.50%, SNSE is doing worse than 71.40% of the companies in the same industry.
  • SNSE has a Return On Equity of -104.92%. This is comparable to the rest of the industry: SNSE outperforms 44.89% of its industry peers.
Industry RankSector Rank
ROA -87.5%
ROE -104.92%
ROIC N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
SNSE Yearly ROA, ROE, ROICSNSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

  • SNSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNSE Yearly Profit, Operating, Gross MarginsSNSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

  • SNSE has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SNSE has less shares outstanding
  • The debt/assets ratio for SNSE has been reduced compared to a year ago.
SNSE Yearly Shares OutstandingSNSE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
SNSE Yearly Total Debt VS Total AssetsSNSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -14.23, we must say that SNSE is in the distress zone and has some risk of bankruptcy.
  • SNSE has a Altman-Z score of -14.23. This is in the lower half of the industry: SNSE underperforms 78.41% of its industry peers.
  • SNSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.23
ROIC/WACCN/A
WACCN/A
SNSE Yearly LT Debt VS Equity VS FCFSNSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • SNSE has a Current Ratio of 5.81. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
  • SNSE's Current ratio of 5.81 is fine compared to the rest of the industry. SNSE outperforms 61.36% of its industry peers.
  • SNSE has a Quick Ratio of 5.81. This indicates that SNSE is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of SNSE (5.81) is better than 62.69% of its industry peers.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
SNSE Yearly Current Assets VS Current LiabilitesSNSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 19.62% over the past year.
EPS 1Y (TTM)19.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 8.36% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.93%
EPS Next 2Y25.37%
EPS Next 3Y13.75%
EPS Next 5Y8.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SNSE Yearly Revenue VS EstimatesSNSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 50M 100M 150M
SNSE Yearly EPS VS EstimatesSNSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SNSE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNSE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNSE Price Earnings VS Forward Price EarningsSNSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNSE Per share dataSNSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

  • SNSE's earnings are expected to grow with 13.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.37%
EPS Next 3Y13.75%

More info and screens

0

5. Dividend

5.1 Amount

  • SNSE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SENSEI BIOTHERAPEUTICS INC

NASDAQ:SNSE (1/16/2026, 8:00:02 PM)

10.44

-1.17 (-10.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-26
Inst Owners4.04%
Inst Owner Change0%
Ins Owners2.23%
Ins Owner Change-0.27%
Market Cap13.15M
Revenue(TTM)N/A
Net Income(TTM)-24.14M
Analysts82.5
Price Target33.15 (217.53%)
Short Float %4.71%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.6%
Min EPS beat(2)13.65%
Max EPS beat(2)31.55%
EPS beat(4)2
Avg EPS beat(4)4.21%
Min EPS beat(4)-18.53%
Max EPS beat(4)31.55%
EPS beat(8)5
Avg EPS beat(8)2.63%
EPS beat(12)9
Avg EPS beat(12)4.93%
EPS beat(16)11
Avg EPS beat(16)3.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.55%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-19.13
EYN/A
EPS(NY)-10.28
Fwd EYN/A
FCF(TTM)-17.78
FCFYN/A
OCF(TTM)-17.76
OCFYN/A
SpS0
BVpS18.26
TBVpS18.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -87.5%
ROE -104.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.12%
ROA(5y)-54.36%
ROE(3y)-59.37%
ROE(5y)-66.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z -14.23
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.02%
Cap/Depr(5y)183.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.59%
EPS Next Y20.93%
EPS Next 2Y25.37%
EPS Next 3Y13.75%
EPS Next 5Y8.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.94%
EBIT Next 3Y0.09%
EBIT Next 5YN/A
FCF growth 1Y37.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.85%
OCF growth 3YN/A
OCF growth 5YN/A

SENSEI BIOTHERAPEUTICS INC / SNSE FAQ

Can you provide the ChartMill fundamental rating for SENSEI BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to SNSE.


What is the valuation status of SENSEI BIOTHERAPEUTICS INC (SNSE) stock?

ChartMill assigns a valuation rating of 0 / 10 to SENSEI BIOTHERAPEUTICS INC (SNSE). This can be considered as Overvalued.


How profitable is SENSEI BIOTHERAPEUTICS INC (SNSE) stock?

SENSEI BIOTHERAPEUTICS INC (SNSE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SENSEI BIOTHERAPEUTICS INC?

The Earnings per Share (EPS) of SENSEI BIOTHERAPEUTICS INC (SNSE) is expected to grow by 20.93% in the next year.